ARTICLE | Clinical News
AltaRex completes Phase II/III
September 4, 2001 7:00 AM UTC
AltaRex (ALXFF; TSE:AXO) completed a 345-patient Phase II/III trial of OvaRex MAb, a murine monoclonal antibody (MAb) against CA125 to treat ovarian cancer. The primary endpoints in the placebo-contro...